Drugs / idraparinux
idraparinux
also known as
SR34006 · idraparinux sodium · Idraparinux de sodio · Idraparinux nonasodium salt · Idraparinux sodique · ORG-34006 · SanOrg34006
targets F10 via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT00071279 | Nov 2003 → Dec 2005 | pulmonary embolism, venous thromboembolism | Sanofi | Completed | Mixed |
| Phase 3 | NCT00070655 | Sep 2003 → Mar 2006 | atrial fibrillation | Sanofi | Completed | Mixed |
| Phase 3 | NCT00062803 | Jun 2003 → Oct 2005 | pulmonary embolism | Sanofi | Completed | Missed primary |
| Phase 3 | NCT00067093 | May 2003 → Sep 2005 | venous thromboembolism | Sanofi | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00311090 Comparator | Apr 2006 → Jan 2008 | venous thromboembolism | Sanofi | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | idraparinux | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00070655 ↗ |
| Known as | Idraparinux de sodio | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314801 ↗ |
| Known as | Idraparinux nonasodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314801 ↗ |
| Known as | Idraparinux sodique | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314801 ↗ |
| Known as | idraparinux sodium | “SR34006 (idraparinux sodium) Injection” NCT00070655 ↗1“SR34006 (idraparinux sodium) Injection” NCT00071279 ↗ |
| Known as | ORG-34006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314801 ↗ |
| Known as | SanOrg34006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00067093 ↗ |
| Known as | SR34006 | “SR34006 (idraparinux sodium) Injection” NCT00070655 ↗ |
| Action | Inhibit | “Idraparinux is an inhibitor of activated factor X (FXa) with a long half-life allowing once-weekly dosing.” PMID 20088937 ↗ Jan 20101“Coagulation factor X inhibitor” CHEMBL5314801 ↗ |
| Route | Subcutaneous | “subcutaneous idraparinux (2.5 mg weekly)” PMID 18294998 ↗ Jan 2008 |
| Target | F10 | “Coagulation factor X inhibitor” CHEMBL5314801 ↗ |